New aspects in the treatment of asthma: Targeted therapy

Chinese Medical Journal

Volumn 121, Issue 7, 2008, Pages 640-648

  Wang, Zeng Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Asthma; Cytokines; IgE; T cell; Targeted therapy

Indexed keywords

ADALIMUMAB; ALTRAKINCEPT; ANTIBIOTIC AGENT; AVE 5883; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CD4 ANTIGEN; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 6; LONG ACTING DRUG; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEPOLIZUMAB; NEUROKININ 1 RECEPTOR ANTAGONIST; OMALIZUMAB; PLACEBO; RESLIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; CYTOKINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; ATOPY; BRONCHUS HYPERREACTIVITY; CD4+ T LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG USE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LOADING DRUG DOSE; MILIARY TUBERCULOSIS; MODERATE PERSISTENT ASTHMA; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; RISK FACTOR; SERUM SICKNESS; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PATHOGENESIS; DRUG ANTAGONISM; IMMUNOLOGY; PHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; CYTOKINES; HUMANS; INTERLEUKIN-5; RECEPTORS, INTERLEUKIN-4; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46449084190     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804010-00013     Document Type: Article

References (50)

1. Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, et al. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 2004; 169: 860-867.
2. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006; 355: 973-975.
3. Jiang H, Chess L. Regulation of immune responses of by T cells. N Engl J Med 2006; 354: 1166-1176.
4. Jeal H. Draper A. Harris J, Taylor AN. Cullinan P. Jones M. Modified Th2 responses at high-dose exposures to allergen using an occupational model. Am J Respir Crit Care Med 2006; 174: 21-25.
5. O'Byrne PM. Cytokines or their antagonists for the treatment for asthma. Chest 2006; 130: 244-256.
6. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001; 107: 429-440.
7. Sabroe I, Parker LC, Dockrell DH, Davies DE, Dower SK, Whyte MK. Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Mcd 2007; 175: 306-311.
8. + invariant T-cell-receptor natural killer T cell in bronchial asthma. N Engl J Med 2006: 354: 1117-1129.
9. Kay AB. Natural Killer T cells and asthma. N Engl J Med 2006; 354: 1186-1188.
10. Thomas SY, Lilly CM, Luster AD. Invariant natural killer T cells in bronchial asthma. N Engl J Med 2006; 354: 2613-2616.
11. Vijayanand P, Seurmois G, Pichard C, Powell RM, Angeo, G, Sarmmut D, et al, Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med 2007 356: 1410-1422.
12. Bratke K, Julius P, Virchow JC. Invariant natural killer T cells in obstructive pulmonary diseases. N Engl J Med 2007; 357: 194-195.
13. Heron M, Claessen AM, Grutters JC. Invariant natural killer T cells in obstructive pulmonary diseases. N Engl J Med 2007; 357: 194.
14. + T cells in atopic asthma. Am J Respir Crit Care Med 2005; 171: 224-230.
15. Wills-karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001; 107: 9-18.
16. Wenzel SE, Balzar S, Ampleford E, Hawkins GA, Busse WW, Calhoun WJ, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respr Crit Care Med 2007; 175: 570-576.
17. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963-970.
18. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-2148.
19. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophils role remains uncertain as anti-interleukin-5 only partially deplete numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199-204.
20. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112: 1029-1036.
21. Kips J, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA. Postma DS. et al. Fffect of SCH55700. a humanized anti-human interleukin-5 antibody, in severe persistent asthma, a pilot study. Am J Reppir Crit Care Med 2003; 167: 1655-1659.
22. Lundblad LK, Thompson-Figueroa J, Leclair J, Sullivan MJ, Poynter ME, Irvin CG, et al. Tumor necrosis factor-a over-expression in lung diseases: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005; 171: 1363-1370.
23. Thomas PS. Tumor necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001; 79: 132-140.
24. Babu KS, Davies DE, Holgate ST. Role of tumor necrosis factor alpha in asthma. Immunol Allergy Clin North Am 2004; 24: 583-597.
25. Gao J, Shan G, Sun B, Thompson PJ, Gan X. Association between polymorphism of tumor necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax 2006; 61: 466-471.
26. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005; 183: 205-208.
27. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018.
28. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J. Respir Crit Care Med 2006; 174: 753-762.
29. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
30. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006; 354: 754-758.
31. Oliveri C, Polosa R. Tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 2074-2075.
32. van Vollenhoven RF. Switching between anti-tumor necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007; 66: 849-851.
33. Malipeddi AS, Rajendran R, Kallarackal G. Disseminated tuberculosis after anti-TNF-alpha treatment. Lancet 2007; 369 (9556): 162.
34. Iizuka M, Watanabe S. Disseminated tuberculosis after anti-TNF-alpha treatment. Lancet 2007; 370 (9587): 564.
35. Krouwels FH. Anti-tumor necrosis factor alpha in asthma. Am J Respir Crit Care Med 2007; 175: 288.
36. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934.
37. Moore WC, Peters SP. Update in asthma 2006. Am J Respir Crit Care Med 2007; 175: 649-654.
38. Bacharier LB, Geha RS. Molecular mechanisms of IgE regulation. J Allergy Clin Immunol. 2000; 105 (2 Pt 2): S547-S558.
39. Boushey HA Jr. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001; 108 (2 Suppl): S77-S83.
40. Busse W. Corren J. Lanier BQ. McAlary M. Fowler-Taylor A. Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190.
41. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces asthma exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-261.
42. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-639.
43. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
44. Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117: 759-766.
45. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695.
46. Massanari M, Maykut RJ, Zeldin RK, Kianifard F, Geba GP. Addition of omalizumab improves lung function and treatment effectiveness in patients with moderate-severe persistent allergic asthma adequately controlled with inhaled steroids and long-acting deta-agonist. Chest 2006; 130 (suppl): 109s.
47. Massanari M, Hodgecock S, Fox H, Surreyk, Zddin R, Reisner C, et al. Add on omalizumab to current asthma theray substantially decreased the risk of future exacevbialions when given after hospitalization due to a severe exacerbation. Proc Am Thorac Soc 2006; 3 (Abst): A59.
48. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355: 1281-1282.
49. Chandhuri N, Whyte MK, Sabroe I. Reducing the toll of inflammatory lung disease. Chest 2007; 131: 1550-1556.
50. Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, et al. Effect of an NK1/NK2 receptor antagonist on airway response and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007: 175: 450-457.